Skip to content
Screener

Arcus Biosciences RCUS Net Income

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.32B+153%
Merck & Co. logo
Merck & Co.MRK
-$1.34B-130%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
AbbVie logo
AbbVieABBV
$3.62B+284%
Immunome logo
ImmunomeIMNM
-$53.84M-29.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.8M-388%

Segments

By segment

See full
Reportable segment-$91M—

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M—
EPS (diluted)-$0.72—

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-—
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%—

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044

FAQ

What is Arcus Biosciences's net income?
Arcus Biosciences (RCUS) reported net income of -$91M in Q2 2026.
What is the long-term trend for Arcus Biosciences's net income?
Over 4 years (2021 to 2025), Arcus Biosciences's net income has grown at a 60.6% compound annual growth rate (CAGR), from $53M to -$353M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Arcus Biosciences's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude